miransertib   Click here for help

GtoPdb Ligand ID: 9429

Synonyms: ARQ 092 | ARQ-092 | compound 21a [PMID: 27305487]
PDB Ligand
Compound class: Synthetic organic
Comment: Miransertib (ARQ-092) is an orally active, selective, and potent allosteric AKT inhibitor [1], being developed for antineoplastic potential.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 4
Topological polar surface area 95.12
Molecular weight 432.21
XLogP 5.08
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES Nc1ncccc1c1nc2c(n1c1ccc(cc1)C1(N)CCC1)nc(cc2)c1ccccc1
Isomeric SMILES Nc1ncccc1c1nc2c(n1c1ccc(cc1)C1(N)CCC1)nc(cc2)c1ccccc1
InChI InChI=1S/C27H24N6/c28-24-21(8-4-17-30-24)25-32-23-14-13-22(18-6-2-1-3-7-18)31-26(23)33(25)20-11-9-19(10-12-20)27(29)15-5-16-27/h1-4,6-14,17H,5,15-16,29H2,(H2,28,30)
InChI Key HNFMVVHMKGFCMB-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Miransertib (ARQ-092) has progressed to Phase 1/2 development in solid and liquid tumours (click here to link to ClinicalTrials.gov's full list of ARQ-092 trials). ARQ-092 is also being evaluated for its potential to inhibit somatic over-growth in patients with Proteus syndrome [2], which is reported to be driven by mosaicism for the E17K activating AKT1 mutation.